Business Context and Reporting Period
This filing is a Form 10-Q for TASER International, Inc. (the filing predates the company’s later AXON Enterprise name) for the three months ended March 31, 2012. The company develops and sells electronic control devices, accessories, training and video evidence-management products and services, including AXON and EVIDENCE.COM. Operations are reported in two segments: ECD and Video.
Key Financial Metrics
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Net sales | $25.6 million | $23.1 million | Up 10.9% |
| Gross margin | $15.2 million; 59.4% | $12.2 million; 52.8% | Up $3.0 million |
| Operating income | $6.5 million; 25.2% | $0.1 million; 0.5% | Up $6.3 million |
| Net income | $3.8 million; 14.8% | $19,732; 0.1% | Up $3.8 million |
| Diluted EPS | $0.07 | $0.00 | Improved |
| Operating cash flow | $3.7 million | $4.4 million | Down $0.7 million |
ECD revenue was $24.8 million, or 97% of total sales, compared with $22.2 million in the prior-year quarter. Video revenue was $0.9 million, essentially flat year over year, while the Video segment generated a $3.0 million operating loss. The TASER X2 contributed $3.2 million of Q1 revenue and was a principal growth driver.
At March 31, 2012, cash and cash equivalents were $24.3 million and short-term investments were $5.3 million, for total cash, cash equivalents and investments of $29.7 million. Total assets were $107.9 million, total liabilities were $20.8 million and stockholders’ equity was $87.0 million. The company had no borrowings under its $10.0 million revolving credit facility and reported compliance with its debt covenants. The facility matures June 30, 2013.
Operating cash flow was reduced by a $2.5 million increase in accounts receivable, partly reflecting higher sales and collection timing. Investing cash use was $0.6 million, including capital expenditures and intangible-asset purchases. Financing cash flow was $15,000 from stock-option exercises; no share repurchases occurred during the quarter.
Material Changes Versus the Prior Comparable Period
- Sales increased 10.9%, primarily from adoption of the TASER X2 and a significant U.S. Army order for X26 devices.
- Gross margin expanded to 59.4% from 52.8%, driven by ECD manufacturing efficiencies and favorable product mix.
- Sales, general and administrative expense declined 5.3% to $8.9 million, and research and development expense declined 22.5% to $2.1 million.
- Operating results benefited from a $2.2 million reversal of previously accrued litigation judgment expense related to the Turner case. This was a significant unusual item and materially affected the year-over-year earnings comparison.
- International sales decreased to approximately $4.0 million, or 16% of total sales, from approximately $5.3 million, or 23%.
- Weighted-average basic shares declined to 55.7 million from 62.4 million, primarily reflecting prior-period share repurchases.
Guidance, Outlook, Risks, Contingencies and Unusual Items
The filing does not provide formal revenue or earnings guidance. Management stated that expected operating cash generation, existing cash and investments, and the available credit facility were expected to be sufficient to finance operations and strategic initiatives during 2012 and 2013, but cautioned that future cash generation and financing availability were not assured.
Management estimated a 2012 effective tax rate of approximately 42.2% before discrete adjustments. The first-quarter effective rate was 41.1%. Net deferred tax assets totaled approximately $20.9 million, including a $1.4 million valuation allowance for an Arizona research and development credit carryforward. Unrecognized tax benefits totaled approximately $2.0 million; recognition could favorably affect the effective tax rate.
The company was a defendant in 37 product-related lawsuits. In the Turner case, the court ultimately adjusted the jury award to $5.5 million after an original $10.0 million verdict. The company recorded a $1.1 million reserve after reversing $2.2 million of previously accrued expense and appealed the case. The company estimated uninsured exposure at approximately $1.1 million; additional litigation could exceed insurance coverage, particularly for claims relating to exhausted policy years.
Other risks include product-liability claims, adverse publicity, dependence on the X26 and X2 product lines, acceptance of AXON and EVIDENCE.COM, data-security and service outages, intellectual-property litigation, regulatory changes, foreign-currency exposure, supplier and component risks, inventory obsolescence and the ability to scale manufacturing.
On April 25, 2012, the board authorized a new $20.0 million share-repurchase program. Through May 9, 2012, the company had repurchased 454,576 shares for approximately $2.2 million under that authorization. The filing also states that there were no off-balance-sheet arrangements.
Important Facts for Investors to Verify
- Confirm the legal entity and ticker history because the filing is for TASER International, Inc., while the requested company name is AXON Enterprise, Inc.
- Separate recurring operating performance from the $2.2 million litigation-reserve reversal when assessing Q1 profitability.
- Monitor the Turner appeal, the remaining $1.1 million reserve and potential uninsured exposure from other product-liability matters.
- Assess whether the Video segment can reduce its $3.0 million quarterly operating loss and achieve meaningful scale.
- Evaluate sustainability of the 59.4% gross margin, particularly the contribution from product mix and manufacturing efficiencies.
- Review concentration risk: two distributors represented approximately 12.2% and 11.7% of Q1 sales, and two customers represented 19.4% and 15.8% of accounts receivable.
- Track the use of cash for the newly authorized share repurchase program and its effect on liquidity and share count.
- Verify the realizability of deferred tax assets and the resolution of approximately $2.0 million of unrecognized tax benefits.